TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02616042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Centella asiatica and bamboo salt
Description: Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Centella asiatica and bamboo salt
Description: Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Centella asiatica and bamboo salt
Description: Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Centella asiatica
Description: Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Centella asiatica
Description: Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Centella asiatica
Description: Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.
Study: NCT05339503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enamel microabrasion
Description: It is a non-restorative, conservative treatment that works both chemically and mechanically to remove up to 0.2 mm of affected enamel per application. Pumice either mixed with 18% hydrochloric acid or 5.25% sodium hypochlorite was used to remove fluorosis stains.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enamel microabrasion
Description: It is a non-restorative, conservative treatment that works both chemically and mechanically to remove up to 0.2 mm of affected enamel per application. Pumice either mixed with 18% hydrochloric acid or 5.25% sodium hypochlorite was used to remove fluorosis stains.
Study: NCT01983358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-289
Description: PARP-1 inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03404479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein
Description: For 12 weeks, administered twice a day by oral.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacerein
Description: For 12 weeks, administered twice a day by oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: For 12 weeks, administered twice a day by oral.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: For 12 weeks, administered twice a day by oral.
Study: NCT01809873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance based incentives
Description: Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
Study: NCT02280564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coaching with technology support
Description: Intensive behavior change support. Engaging participants to take an active role in their diabetes care using motivational interviewing, technology, family communication, problem solving skills.
Study: NCT00452491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: 0.2 IU/kg/day 7 days per week given continuously for 3 years
Study: NCT04528745

Intervention type: DIAGNOSTIC_TEST
Intervention: Bio Impedance Spectroscopy (BIS)
Description: Determination of fat free mass by BIS
Study: NCT01799616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study: NCT04444414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: bilateral manipulation lumbosacral, hip joint gapping, stretching the hip rotators with hip and knee flexion, femorotibial gapping, decompression of connective tissue of the patellofemoral region, internal and external joint line opening in laterality, mobilization of the base of the fibula, tibiofibular-talus gapping, and muscle strengthening.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group received no treatment, they only attended the evaluations.
Study: NCT02478554

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Customized fetal growth curves
Description: Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
Study: NCT03144674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib at the protocol-defined dose.
Study: NCT03621852

Intervention type: DEVICE
Intervention: Endoultrasound guided FNB
Description: EUS FNB with Aquire TM device
Study: NCT01848756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
Study: NCT02245412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1007 10 mg/kg once weekly
Description: ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1007 20 mg/kg once weekly
Description: ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1007 20 mg/kg twice weekly
Description: ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
Study: NCT02075658

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirSeal® System-Interventional
Description: The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Insufflator and Trocar
Description: Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
Study: NCT01899534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-screening
Description: E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
Study: NCT02391987

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tele-monitoring and health coaching
Description: Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.~Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management.
Study: NCT03277924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 100 MG/10 ML [Opdivo]
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT05772936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: perturbation induce step training to improve reactive stepping with paretic leg.
Study: NCT01815125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
Study: NCT03590613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
Study: NCT03289169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDITOXIN®
Description: 20U of Meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
Study: NCT03794869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous electrostimulation treatment (EPS)
Description: Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of CORE.
Study: NCT01646203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-TR1
Description: Administered intravenously
Study: NCT00186537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss
Study: NCT02696408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.~If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.~If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only.
Study: NCT02403895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label AZD2014
Description: Dual TORC1/TORC2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Taxane
Study: NCT03913845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine with epinephrine
Description: One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline with epinephrine
Description: Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
Study: NCT04594460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03
Description: the experimental arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) ,the treatment duration will be 8 hours per day, for 12 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OLO-1 Medical Molecular Sieve Oxygen Generator
Description: the control arm will receive oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.)the treatment duration will be 8 hours per day, for 12 weeks.
Study: NCT03023696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Cervical Keyhole Foraminotomy
Description: Under microscopic or loop magnification, a high-speed burr is used to perform the foraminotomy. The keyhole foraminotomy begins at the lamina-facet junction, with careful consideration of the amount of facet resection. Typically, only the medial one third is drilled. Then a 1- or 2-mm Kerrison punch can be carefully placed over the nerve root and then used to undercut the facet, ensuring that the spine is not destabilized by the foraminotomy. The amount of facet resection must not exceed 50% in order to preserve spine stability.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Decompression
Description: Cervical decompression for myelopathy, including the following procedures: laminoplasty, laminectomy, discectomy and fusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Decompression
Description: Cervical decompression for myelopathy, including the following procedures: laminoplasty, laminectomy, discectomy and fusion
Study: NCT02707211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-oxLDL IgM antibody
Description: Immunization
Study: NCT01815125

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLacebo
Description: placebo
Study: NCT03613051

Intervention type: BEHAVIORAL
Intervention: Movement Assessment Battery for children
Description: this test measures manual dexterity , balance , aiming and catching

Intervention type: BEHAVIORAL
Intervention: Movement Assessment Battery for children
Description: this test measures manual dexterity , balance , aiming and catching

Intervention type: BEHAVIORAL
Intervention: Movement Assessment Battery for children
Description: this test measures manual dexterity , balance , aiming and catching
Study: NCT02408393

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study: NCT00437099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor®
Description: arm 1: Omacor 1680 Arm 2: Omacor 3360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacor®
Description: arm 1: Omacor 1680 Arm 2: Omacor 3360

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03158051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring
Description: Intervention arm participants will receive a home blood pressure monitor, home blood pressure log, and training on accurate home monitoring. They will be asked to share their home blood pressure readings during health coach telephone calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Health Coaching
Description: Intervention arm participants will receive a health coach phone call every 2 weeks for 6 months, for a total of 12 calls. During each call, the health coach will review and discuss home blood pressures and address barriers and concerns to hypertension management. During each telephone call, the coach will guide the participant on selecting health behavior goals. Intervention arm participants will also receive handouts about hypertension management during the study visits and after health coach calls.
Study: NCT01851564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-expanding mesh-metal oesophageal stent (SEMS)
Description: A removable stent designed for the treatment of bleeding oesophageal varices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-expanding mesh-metal oesophageal stent (SEMS)
Description: A removable stent designed for the treatment of bleeding oesophageal varices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard Medical and Endoscopic Therapy
Study: NCT01651832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCAN
Description: The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
Study: NCT01851564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard Medical and Endoscopic Therapy
Study: NCT02588833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor
Study: NCT04478357

Intervention type: DRUG
Group type: OTHER
Intervention: 4 mg Fesoterodine ER tablet from Zwickau
Description: Manufactured at Zwickau

Intervention type: DRUG
Group type: OTHER
Intervention: 4 mg fesoterodine ER tablet from Freiburg
Description: Manufactured at Freiburg

Intervention type: DRUG
Group type: OTHER
Intervention: 8 mg fesoterodine ER tablet from Zwickau
Description: Manufactured at Zwickau

Intervention type: DRUG
Group type: OTHER
Intervention: 8 mg fesoterodine ER tablet from Freiburg
Description: Manufactured at Freiburg
Study: NCT02047747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
Study: NCT03277924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT02330523

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: allograft + x-link collagen membrane
Description: Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: xenograft + non-x-link collagen
Description: Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.